Lytix Biopharma AS (OSL:LYTIX) Interest Coverage: N/A (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

OSL:LYTIX Lytix Biopharma AS OSL:LYTIX
28 GF Score
Price kr8.74
GF Value kr0.17
Valuation Significantly Overvalued
! 2 Warning Signs
View Full Analysis

What is Lytix Biopharma AS Interest Coverage?

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income by its Interest Expense. Lytix Biopharma AS's Operating Income for the three months ended in Mar. 2026 was kr-26.80 Mil. Lytix Biopharma AS's Interest Expense for the three months ended in Mar. 2026 was kr0.00 Mil. GuruFocus does not calculate 's interest coverage with the available data. The higher the ratio, the stronger the company's financial strength is.

The historical rank and industry rank for Lytix Biopharma AS's Interest Coverage or its related term are showing as below:


OSL:LYTIX's Interest Coverage is not ranked *
in the Biotechnology industry.
Industry Median: 104.025
* Ranked among companies with meaningful Interest Coverage only.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.


Lytix Biopharma AS  (OSL:LYTIX) Interest Coverage Explanation

Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.

Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .


Lytix Biopharma AS Interest Coverage Related Terms


Lytix Biopharma AS Interest Coverage Historical Data

* Premium members only.

The historical data trend for Lytix Biopharma AS's Interest Coverage can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

Lytix Biopharma AS Interest Coverage Chart

Lytix Biopharma AS Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Interest Coverage
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

Lytix Biopharma AS Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Interest Coverage Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only N/A 0.00 N/A 0.00 N/A

OSL:LYTIX vs VRTX, REGN, ALNY: Interest Coverage Comparison

For the Biotechnology subindustry, Lytix Biopharma AS's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Lytix Biopharma AS Interest Coverage vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Lytix Biopharma AS's Interest Coverage distribution charts can be found below:

* The bar in red indicates where Lytix Biopharma AS's Interest Coverage falls into.


OSL:LYTIX
28GF Score
Lytix Biopharma AS OSL:LYTIX
Interest Coverage is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Lytix Biopharma AS Interest Coverage Calculation

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:

If Interest Expense is negative and Operating Income is positive, then

Interest Coverage=-1* Operating Income /Interest Expense

Else if Interest Expense is negative and Operating Income is negative, then

The company did not have earnings to cover the interest expense.

Else if Interest Expense is 0 and Long-Term Debt & Capital Lease Obligation is 0, then

The company had no debt (1).


Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Lytix Biopharma AS's Interest Coverage for the fiscal year that ended in Dec. 2025 is calculated as

Here, for the fiscal year that ended in Dec. 2025, Lytix Biopharma AS's Interest Expense was kr-0.21 Mil. Its Operating Income was kr-64.03 Mil. And its Long-Term Debt & Capital Lease Obligation was kr1.22 Mil.

Lytix Biopharma AS did not have earnings to cover the interest expense.

Lytix Biopharma AS's Interest Coverage for the quarter that ended in Mar. 2026 is calculated as

Here, for the three months ended in Mar. 2026, Lytix Biopharma AS's Interest Expense was kr0.00 Mil. Its Operating Income was kr-26.80 Mil. And its Long-Term Debt & Capital Lease Obligation was kr0.99 Mil.

GuruFocus does not calculate Lytix Biopharma AS's interest coverage with the available data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The higher the ratio, the stronger the company's Financial Strength is.

Is Lytix Biopharma AS (OSL:LYTIX) Overvalued in 2026?

Based on GuruFocus' analysis, Lytix Biopharma AS stock appears to be overvalued. The current stock price of kr8.74 is trading 5041.2% above its estimated GF Value™ of kr0.17. GuruFocus considers Lytix Biopharma AS to be Significantly Overvalued.

Key valuation signals for OSL:LYTIX:

  • Interest Coverage: N/A
  • GF Value™: kr0.17 vs. price of kr8.74 (5041.2% above fair value)
  • GF Score™: 28/100 with 2 warning signs

No single metric tells the full story. See the OSL:LYTIX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Lytix Biopharma AS Business Description

Address Sandakerveien 138, Oslo, NOR, 0484
Lytix Biopharma AS is a clinical-stage biotech company engaged in developing cancer immunotherapies aimed at activating the patient's immune system to fight cancer. The company's technology platform is designed to convert immunologically "cold" tumors into "hot" tumors by releasing tumor antigens and activating tumor-specific immune responses. The product pipeline of the company includes LTX-401 and LTX-315. The company operates in Norway and the USA, majority of revenue is from the USA.
28GF Score

Get the complete analysis for OSL:LYTIX

Interest Coverage is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr8.74
Price
kr0.17
GF Value